X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (99) 99
index medicus (90) 90
oncology (55) 55
female (51) 51
middle aged (48) 48
aged (45) 45
adult (39) 39
breast cancer (36) 36
chemotherapy (34) 34
cancer (32) 32
randomized controlled trials as topic (28) 28
medicine, general & internal (27) 27
survival (25) 25
male (24) 24
treatment outcome (23) 23
therapy (21) 21
research (20) 20
analysis (19) 19
anticoagulants - therapeutic use (17) 17
care and treatment (17) 17
risk factors (17) 17
anticoagulants - adverse effects (16) 16
cell biology (16) 16
double-blind (16) 16
neoplasms - mortality (16) 16
aged, 80 and over (15) 15
breast neoplasms - drug therapy (15) 15
breast neoplasms - pathology (15) 15
hemorrhage - chemically induced (15) 15
heparin, low-molecular-weight - therapeutic use (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
cell lung-cancer (14) 14
low-molecular-weight (14) 14
metastasis (14) 14
retrospective studies (14) 14
anticoagulants - administration & dosage (13) 13
body mass index (13) 13
deep-vein thrombosis (13) 13
immunohistochemistry (13) 13
prognosis (13) 13
randomized-trial (13) 13
time factors (13) 13
carcinoma (12) 12
health aspects (12) 12
neoplasms - complications (12) 12
patients (12) 12
survival analysis (12) 12
trastuzumab (12) 12
heparin - adverse effects (11) 11
prevention (11) 11
risk (11) 11
anticoagulants [therapeutic use] (10) 10
cancer patients (10) 10
heparin (10) 10
heparin - therapeutic use (10) 10
heparin, low-molecular-weight [therapeutic use] (10) 10
low-dose warfarin (10) 10
mortality (10) 10
neoplasms (10) 10
pathological complete response (10) 10
phase-ii trial (10) 10
physiology (10) 10
postmenopausal women (10) 10
research paper (10) 10
venous thromboembolism - drug therapy (10) 10
anticoagulants (9) 9
docetaxel (9) 9
heparin - administration & dosage (9) 9
heparin, low-molecular-weight - administration & dosage (9) 9
medicine (9) 9
pulmonary-embolism (9) 9
venous thromboembolism (9) 9
warfarin - administration & dosage (9) 9
biomarkers, tumor - analysis (8) 8
bleeding complications (8) 8
carcinoma, small cell - mortality (8) 8
diagnosis (8) 8
disease-free survival (8) 8
drug therapy (8) 8
efficacy (8) 8
epidemiology (8) 8
expression (8) 8
heparin [therapeutic use] (8) 8
kaplan-meier estimate (8) 8
risk-factors (8) 8
secondary prevention (8) 8
surgery (8) 8
venous thrombosis - prevention & control (8) 8
vitamin k - antagonists & inhibitors (8) 8
administration, oral (7) 7
anticoagulants [administration & dosage; adverse effects] (7) 7
antineoplastic agents - therapeutic use (7) 7
breast neoplasms - mortality (7) 7
breast neoplasms, male - pathology (7) 7
combination (7) 7
dna damage (7) 7
dosage and administration (7) 7
endocrine therapy (7) 7
fasting glucose (7) 7
growth (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 12, Issue 12, p. CD006652
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2018, Volume 2018, Issue 1, p. CD006649
Journal Article
Future Oncology, ISSN 1479-6694, 07/2017, Volume 13, Issue 17, pp. 1517 - 1525
Aim: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for... 
eribulin mesylate | Edmonton symptoms assessment scale | quality of life | metastatic breast cancer | CAPECITABINE | MESYLATE | ONCOLOGY | QUALITY-OF-LIFE | SCALE
Journal Article
JOURNAL OF CLINICAL MEDICINE, ISSN 2077-0383, 02/2019, Volume 8, Issue 2, p. 254
Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic... 
CARDIAC-FUNCTION | SURVIVAL | HER2 positive breast cancer | real-world settings | FOLLOW-UP | RANDOMIZED-TRIAL | efficacy | ADJUVANT TRASTUZUMAB | PACLITAXEL | trastuzumab | MEDICINE, GENERAL & INTERNAL | NEOADJUVANT CHEMOTHERAPY | TREATMENT PATTERNS | CHEMOTHERAPY PLUS TRASTUZUMAB | long-term safety | CLINICAL-OUTCOMES
Journal Article
Journal Article